Objective-Deep vein thrombosis results from a combination of risk factors including genetic conditions, obesity, drugs, pregnancy, aging, and malignancy. We examined pathophysiological roles of the TNF-α (tumor necrosis factor-α)-TNFRp55 (tumor necrosis factor receptor p55) axis in thrombus resolution using Tnfrp55 −/− (TNF-Rp55-deficient) mice. Approach and Results-On ligating the inferior vena cava of wild-type (WT) mice, venous thrombi formed and grew progressively until 5 days but shrunk to <50% of the thrombus weight at day 14. Concomitantly, inferior vena cava ligation enhanced intrathrombotic gene expression of Tnfa and Tnfrp55, and intrathrombotic macrophages expressed both TNF-α and TNF-Rp55 proteins. In Tnfrp55 −/− mice treated with the same manner, thrombus formed at a similar rate for 5 days, but shrinking was delayed compared with WT mice. Moreover, the blood flow recovery in thrombosed inferior vena cava was suspended in Tnfrp55 −/− mice compared with WT mice. Intrathrombotic Plau (urokinase-type plasminogen activator), Mmp2 (matrix metalloproteinase 2), and Mmp9 (matrix metalloproteinase 9) mRNA expression was significantly reduced in Tnfrp55 −/− mice, compared with WT ones. Supportingly, the administration of anti-TNF-α antibody or TNF-α inhibitor (etanercept) delayed the thrombus resolution in WT mice. Furthermore, TNF-α treatment enhanced gene expression of Plau, Mmp2, and Mmp9 in WT macrophages but not Tnfrp55 −/− macrophages. These effects were significantly suppressed by ERK (extracellular signal regulated kinase) and NF-κB (nuclear factor-kappa B) inhibitors. Therefore, the lack of TNF-Rp55 has detrimental roles in the thrombus resolution by suppressing PLAU, MMP-2, and MMP-9 expression. In contrast, TNF-α administration accelerated thrombus resolution in WT but not Tnfrp55 −/− mice. Key Words: matrix metalloproteinase ◼ thrombosis ◼ tumor necrosis factor-α ◼ tumor necrosis factor receptor p55 ◼ urokinase-type plasminogen activator
V enous thromboembolism (VTE) consists of deep vein thrombosis and pulmonary thromboembolism (PTE). PTE is the third most common cardiovascular disorder and is estimated to be responsible for between 100 000 and 180 000 deaths annually in the United States alone. 1 PTE is often complicated with myocardial infarction and stroke. Moreover, deep vein thrombosis in the lower extremities is frequently complicated with PTE and as a consequence warrants serious health concerns. Out of 38 220 659 patients discharged from United States acute-care hospitals, about 4 000 000 surgical patients and 8 000 000 medical patients were at moderate or high risk for VTE. 2 In a global cross-sectional study, a large proportion of hospitalized patients were also at moderate or high risk for VTE because 42% of medical patients and 64% of surgical patients were estimated to be at risk for VTE. 3 VTE results from a combination of risk factors, including genetic conditions, obesity, drugs, pregnancy, aging, trauma, and malignancy. 4, 5 Among hospitalized medical patients, history of VTE, bed rest, peripherally inserted central venous catheter, and cancer were the 4 of the most prevalent risk factors for VTE. 6 
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The following 3 factors are well known as Virchow triad and are presumed to be involved in the pathogenesis of venous thrombosis: endothelial damages, stasis or turbulence of blood flow, and blood hypercoagulability. Accumulating evidence indicates the involvement of proinflammatory cytokines and chemokines in thrombus formation and resolution. [7] [8] [9] [10] Proinflammatory cytokines can potently activate endothelial cells, increase expression of adhesion molecules by endothelial cells, and promote thrombosis. 11, 12 In contrast, some chemokines can activate leukocytes to accelerate thrombus resolution and intrathrombotic neovascularization. [13] [14] [15] We have previously demonstrated that a proinflammatory cytokine, IFN-γ (interferon-γ), can decelerate thrombus resolution by suppressing collagenolysis. 16 TNF-α (tumor necrosis factor-α) is a pleiotropic inflammatory cytokine produced by a variety of cell types including macrophages, T cells, and keratinocytes. There are 2 distinct types of receptors for TNF-α, 55 kDa and 75 kDa TNF receptors (TNF-Rp55 [tumor necrosis factor receptor p55] and TNF-Rp75 [tumor necrosis factor receptor p75]), exhibiting 30% homology at the amino acid level. 17 TNF-Rp55 is expressed ubiquitously on most cell types except red blood cells, whereas TNF-Rp75 expression is predominantly restricted to hematopoietic cells. 17 TNF-Rp55 mediates various activities of TNF-α, including cytotoxicity, fibroblast proliferation, and induction of superoxide dismutase. Indeed, Tnfrp55 −/− (TNFRp55-deficient) mice were resistant to bacterial infection and liver injury. [18] [19] [20] The absence of TNF-Rp55 reduced the development of colitis-associated colon cancer and accelerated skin wound healing. 21, 22 There are still discrepancies on the roles of TNF-α in chemical-induced arterial thrombosis. [23] [24] [25] Moreover, from the pathological aspects, venous thrombi are different from arterial ones in the mechanism of their formation process. Especially, the formers are mainly attributable to stasis conditions of venous circulation. However, the pathophysiological roles of TNF-α in venous thrombosis still remain unclear. This prompted us to explore the pathophysiological roles of the TNF-α-TNF-Rp55 axis in venous thrombosis using Tnfrp55 −/− mice. In this study, we demonstrate that the absence of TNF-Rp55 did retard resolution of the venous thrombosis, together with suppressed expression of MMP (matrix metalloproteinase)-2, MMP-9, and PLAU (urokinase-type plasminogen activator) compared with WT mice. This may mirror the observation that TNF-α could enhance the gene expression of Plau, Mmp2, and Mmp9 in macrophages in a TNF-Rp55-dependent manner. These observations suggest that the TNF-α-TNF-Rp55 axis may contribute to resolution of venous thrombus.
Materials and Methods
The data that support the findings of this study are available from the corresponding author on reasonable request.
Reagents and Antibodies
Recombinant mouse TNF-α and a specific TNF antagonist, etanercept, were purchased from PeproTech (London, UK) and Wyeth Pharmaceutical Japan, respectively. APDC (a NF-κB [nuclear factor-κB] inhibitor), PD98509 (an ERK [extracellular signal regulated kinase] inhibitor), and SP600125 (a JNK [c-Jun N-terminal kinase] inhibitor) were obtained from Sigma-Aldrich. The following monoclonal antibodies (mAbs) and polyclonal antibodies (pAbs) were used for immunohistochemical and double-color immunofluorescence analyses: rat antimouse F4/80 mAb (Serotec, Oxford, UK), rat antimouse CD31 mAb (BD PharMingen, San Diego, CA), goat anti-TNF-α pAbs, goat anti-TNF-Rp55 pAbs (Santa Cruz Biotechnology, Dallas, TX), rabbit anti-MPO (myeloperoxidase) pAbs (Neomarkers, Fremont, CA), cyanine dye 3-conjugated donkey antirabbit IgG or antigoat IgG pAbs, and FITC-conjugated donkey antirat IgG pAbs (Jackson Immunoresearch Laboratories, West Grove, PA). Western blot analysis was performed by the use of following antibodies: rabbit anti-p38 MAPK (mitogen-activated protein kinase) pAbs, rabbit anti-JNK pAbs, rabbit anti-ERK mAb, rabbit antiphosphorylated (p)-p38 MAPK pAbs, rabbit anti-p-JNK pAbs, rabbit anti-p-ERK pAbs (Cell Signaling Technology, Danvers, MA), rat antimouse Gr-1 mAbs (clone RB6-8C5; BD Bioscience, San Jose, CA), or rabbit antimouse GAPDH mAb (clone 14C10; Cell Signaling Technology).
Mice
Pathogen-free 8-to 10-week-old male BALB/c mice were obtained from Japan SLC (Shizuoka, Japan) and were designated as WT mice in this study. Age-and sex-matched Tnfrp55 -/-mice, which were backcrossed with BALB/c mice for >8 generations, were used in these experiments. [19] [20] [21] [22] All mice were housed individually in cages under the specific pathogen-free conditions during the experiments. To avoid sex-dependent differences in deep vein thrombosis model, we used age-and sex-matched mice during the total course of our study. 1 All animal experiments were approved by the Committee on Animal Care and Use in Wakayama Medical University.
Inferior Vena Cava Ligation-Induced Deep Vein Thrombus Model
Intravenous thrombus formation was induced as previously described. 15, 16 In brief, after deep anesthesia with intraperitoneal injection of pentobarbital (50 mg/kg body weight), a 2-cm incision was made along the abdominal midline. Then, a 21-gauge needle was placed along inferior vena cava (IVC) exposed carefully. IVC was ligated with the needle using 3-0 silk suture, followed by pulling out the needle. This procedure can induce thrombus formation in almost all the mice. In some experiments, WT mice were intraperitoneally given murine recombinant TNF-α (1 μg/mouse in 200 μL PBS), anti-TNF-α mAb (30 μg/mouse in 200 μL PBS), or etanercept (5 mg/kg in 200 μL PBS) at 4, 8, and 12 days after the IVC ligation. At the indicated time intervals after the IVC ligation, mice were euthanized by an overdose of diethyl ether, and intravenous thrombi were harvested for the determination of the weights and other analyses. We used 6 mice per group and repeated all animal experiments at least 3 times. Because we obtained similar results at each experiment, we demonstrated the representative results from the repeated experiments.
Histopathologic Analyses
At the indicated time intervals after the IVC ligation, thrombi were harvested, fixed in 4% formaldehyde buffered with PBS (pH 7.2), and paraffin-embedded sections (4-µm thick) were made. The sections were stained with hematoxylin and eosin or Masson trichrome solution.
Immunohistochemical Analyses
Deparaffinized sections were immersed in 0.3% H 2 O 2 in methanol for 30 minutes to eliminate endogenous peroxidase activities. The sections were further incubated with PBS containing 1% normal serum derived from the same species as the origin of the secondary antibodies and 1% bovine serum albumin to reduce nonspecific reactions. 
Nonstandard Abbreviations and Acronyms

Measurements of Leukocytes and Neovessels
Intrathrombotic leukocytes and vascular density were semiquantitatively evaluated as previously described. Briefly, after F4/80-positive macrophages in 5 high-power fields (×1000) were counted within the thrombus, the total numbers in the 5 fields were combined. Intrathrombotic CD31-positive areas with tube-like formation were counted in 5 high-power fields (×1000) as vascular density, as previously described. 16 All measurements were performed by an examiner without a prior knowledge of the experimental procedures.
Double-Color Immunofluorescence Analysis
Deparaffinized sections or peritoneal macrophages were incubated with PBS containing 1% normal donkey serum and 1% BSA to reduce nonspecific reactions as previously described. 16 Thereafter, the sections were further incubated with the combination of anti-F4/80 and anti-TNF-α or that of anti-F4/80 and anti-TNF-Rp55 antibodies. All antibodies were used at a concentration of 1 µg/mL. After the incubation with fluorochrome-conjugated secondary antibodies (15 µg/mL) at room temperature for 30 minutes, the sections were observed under a fluorescence microscopy. In some experiments, nuclei were stained using 4′,6-diamidino-2-phenylindole (DAPI; Roche Diagnostics) according to the manufacturer's instructions. Negative control test was done as mentioned above.
IVC Blood Flow Measurement by a Laser Doppler
Microvascular IVC blood flow was evaluated by laser Doppler imaging (OMEGAFLO FLO-C1 BV; OMEGAWAVE) as described previously. 16 Blood flow through the exposed IVC region of the interest was assessed, at 3 time points, immediately after laparotomy, immediately after the ligation, and at the harvest. The intensities were reported as the percentage of the baseline blood flow of each animal, to ensure consistency.
Measurement of Intrathrombotic Hydroxyproline Contents
At the indicated time intervals after the IVC ligation, venous thrombi were removed and dried for 16 hours at 120°C. Contents of hydroxyproline, a major constituent of collagen, were measured as the index of collagen accumulation at the thrombi, as described previously. 26 Hydroxyproline content was calculated by comparison to standards and expressed as the amount (µg) per dry weight of the thrombus (mg).
Extraction of Total RNAs and Real-Time Reverse Transcription Polymerase Chain Reaction
Real-time reverse transcription polymerase chain reaction was performed as described previously. 16, 26 Briefly, total RNA was extracted from tissue samples (100 µg) using ISOGENE (Nippon Gene, Toyama, Japan) according to the manufacturer's instructions, and 5 µg of total RNA were reverse-transcribed into cDNA at 42°C for 1 hour in 20 µL reaction mixture containing mouse Moloney leukemia virus reverse transcriptase (PrimeScript; TAKARA BIO) with random 6 primers (TAKARA BIO). Thereafter, generated cDNA was subjected to real-time polymerase chain reaction analysis using SYBR Premix Ex Taq II kit (TAKARA BIO) with the sets of specific primers (Table) . Relative quantity of the target gene expression to β-actin gene was measured by comparative Ct method.
Cell Culture
WT or Tnfrp55
-/-mice were intraperitoneally injected with 2 mL of 3% thioglycollate (Sigma-Aldrich), to obtain intraperitoneal macrophages (macrophage purity >95%) 3 days later as described previously. 16, 27 The resultant cells were judged to consist of more than 95% macrophages as determined by flow cytometry using anti-F4/80 antibody and were suspended in antibiotic-free RPMI (Roswell Park Memorial Institute) 1640 medium containing 10% fetal bovine serum and incubated at 37°C in three 6-well cell culture plates. Two hours later, nonadherent cells were removed, and the medium was replaced. After the cells were incubated for 24 hours in the presence of TNF-α (500 U/ mL), together with APDC (30 µmol/L), PD98509 (15 µmol/L), or SP600125 (10 µmol/L), the cells were applied to subsequent analyses.
Western Blotting
The obtained macrophages were homogenized with a lysis buffer (20 mmol/L Tris-HCl [pH 7.6], 150 mmol/L NaCl, 1% Triton X-100, 1 mmol/L EDTA) containing Complete Protease Inhibitor Cocktail (Roche Diagnostics) and phosphatase inhibitor cocktails for serine/ threonine protein phosphatases and tyrosine protein phosphatases (P2850 and P5726; Sigma-Aldrich) and were centrifuged to obtain lysates. 27 The lysates (equivalent to 30 µg protein) were electrophoresed in a 10% SDS-polyacrylamide gel and were transferred onto a nylon membrane. After the membrane was sequentially reacted with optimally diluted primary antibodies and horse radish peroxidase-conjugated secondary antibodies, the immune complexes were visualized using ECL system (Amersham Biosciences). The band intensities were measured using NIH Image Analysis Software version 1.61 (National Institutes of Health).
ELISA
Thrombi were obtained at the indicated time intervals and were homogenized with 0.3 mL of PBS containing Complete Protease Inhibitor Mixture (Roche Diagnostics, New York, NY). The homogenates were centrifuges at 12 000g for 15 minutes. In another series of experiments, blood samples were obtained at the indicated time intervals and were centrifuged at 1500g for 15 minutes 
Actb indicates β-actin; F, forward primer; Mmp2, matrix metalloproteinase 2; Mmp9, matrix metalloproteinase 9; Pai1, plasminogen activator inhibitor-1; Plau, urokinase-type plasminogen activator; R, reverse primer; RT-PCR, reverse transcription polymerase chain reaction; Tnfa, tumor necrosis factor-α; Tnfrp55, tumor necrosis factor receptor p55.
to obtain sera. The supernatants or sera were subjected to ELISA by using commercially available kits for MMP-2, MMP-9 (R&D, Minneapolis, MN), PLAU, PAI-1 (plasminogen activator inhibitor-1; Molecular Innovations, Novi, MI), TIMP (tissue inhibitor of metalloproteinase)-1, TIMP-2 (RayBiotech, Norcross GA), TIMP-3 (LSBio, Seattle, WA), TIMP-4 (Aviva Systems Biologu, San Diego, CA), or TNF-α (R&D), according to the manufacturer's instructions. The detection limits for each methods were follows: MMP-2, >0.033 ng/mL; MMP-9, >0.007 ng/mL; PLAU, >0.038 ng/ mL; PAI-1, >0.032 ng/mL; TIMP-1, >3 pg/mL; TIMP-2, >80 pg/ mL; TIMP-4, >10 pg/mL; TNF-α, >1.88 pg/mL. Total protein in the supernatant was measured with a commercial kit (BCA Protein Assay Kit; Pierce, Grand Island, NY) using BSA as a standard. The data were expressed as target protein (ng/mL) relative to total protein (mg/mL) for each sample.
Measurement of Prothrombin Time and Activated Partial Thromboplastin Time
Blood samples were taken with 3.8% citrate solution and centrifuged to obtain plasma samples. Prothrombin time and activated partial thromboplastin time of citrated plasma samples were measured by using COAGSEARCH (A&T) according to the manufacturer's instructions.
Statistical Analysis
Data were expressed as the mean±SEM (standard error of measurement). The normality and equal variance of all data could be confirmed by the use of Klomogorov-Smirnov test and Bartlett one, followed by subsequent analyses. For the comparison between WT and Tnfrp55 −/− mice at multiple time points, 2-way ANOVA followed by Dunnett post hoc test was used. To compare the values between the 2 groups, unpaired Student t test were performed. In the series of TNF-α stimulation with several inhibitors in peritoneal macrophages, 1-way ANOVA followed by Dunnett post hoc test was used. P<0.05 was considered statistically significant. All statistical analyses were performed using Statcel3 software under the supervision of a medical statistician, Prof Toshio Shimokawa (Wakayama Medical University).
Results
Intrathrombotic TNF-α and TNF-Rp55 Expression After the IVC Ligation
The detection of TNF-α and TNF-Rp55 in venous thrombus in autopsy cases ( Figure I in the online-only Data Supplement) prompted us to examine intrathrombotic gene expression of Tnfa and Tnfrp55 in mice after IVC ligation. The expression of Tnfa and Tnfrp55 mRNA became detectable in the thrombus at 3 days after the IVC ligation and increased progressively as thrombi grew ( Figure 1A and 1B) . Double-color immunofluorescence analyses revealed that both TNF-α and TNF-Rp55 were mainly detected in F4/80-positive macrophages (Figure 1C and 1D ; Figure II in the online-only Data Supplement). These observations implicated the TNF-α-TNF-Rp55 axis involvement in the formation and resolution of deep vein thrombi in an autocrine and paracrine manner.
Impaired Thrombus Resolution in the Absence of TNF-Rp55
Venous thrombus was detected in WT mice even at 12 hours after IVC ligation and grew progressively for 3 days after ligation, resolving thereafter in WT mice (Figure 2A) . Simultaneously with thrombus resolution, blood flow recovered gradually ( Figure 2B ). IVC ligation caused thrombus formation at a similar speed in Tnfp55 −/− mice as WT mice up to 5 days after the ligation. However, thrombus began to shrink at a slower pace in Tnfp55 −/− mice than in WT mice (Figure 2A) . Consistently, blood flow recovery was delayed in Tnfp55 −/− mice compared with WT mice ( Figure 2B ). At 10 days after the ligation, thrombus sizes were larger in Tnfp55 −/− mice than in WT mice ( Figure 2C ). Moreover, intrathrombotic collagen area was remarkably enhanced in Tnfrp55 -/-mice, compared with WT mice (Figure 2D and 2E) and revealed by Masson staining. 15, 16 Consistently, intrathrombotic contents of hydroxyproline, a major component of collagen, were significantly higher in Tnfrp55 -/-mice at 10 and 14 days after the IVC ligation, than WT mice ( Figure 2F ). We next evaluated the process of intrathrombotic recanalization, which is presumed to be essential for thrombus resolution. 15, 16 Intrathrombotic CD31-positive areas were significantly depressed at 10 and 14 days in Tnfrp55 -/-mice, compared with WT mice ( Figure 2G  and 2H 
Effects of Recombinant TNF-α, Anti-TNF-α mAb, or Etanercept on Thrombus Resolution
The effects of recombinant TNF-α, anti-TNF-α mAb, or etanercept on the resolution of IVC ligation-induced venous thrombi were examined. After IVC ligation, repetitive administration of recombinant TNF-α significantly reduced thrombus weights and accelerated blood flow recovery in thrombosed IVC compared with the control group ( Figure 3A and 3B). Moreover, with this administration schedule, TNF-α was not detected in serum by a specific ELISA. Further, proinflammatory cytokine gene expression was not enhanced in the spleen ( Figure IIIA Figure 3C and 3D) . These observations would indicate that the interaction of TNF-α with TNF-Rp55, but not TNF-Rp75, could regulate the thrombosis resolution and might be a good target to accelerate the thrombus resolution.
Attenuated Expression of MMP-2, MMP-9, and PLAU in Tnfrp55 -/-Mice
The presumed essential roles of MMPs and the plasmin system in venous thrombus resolution encouraged us to examine the intrathrombotic gene expression of Mmp2, Mmp9, Plau, and Pai1 (plasminogen activator inhibitor-1). 15, 16 Until 5 days after the IVC ligation, there were no significant differences in mRNA expression of these molecules between WT and Tnfrp55 -/-mice ( Figure 4A ). However, later than 10 days, the gene expression of Mmp2, Mmp9, and Plau were significantly attenuated in Tnfrp55 -/-mice compared with WT ones, whereas WT and Tnfrp55 -/-mice exhibited similar levels of the gene expression of Pai-1 ( Figure 4A ). Similar expression patterns for MMP-2, MMP-9, PLAU, and PAI-1 protein levels were observed in the thrombus ( Figure 4B ). However, there 
Contribution of Macrophages to Thrombus Formation
Because of the presumed crucial roles of inflammatory responses in thrombus formation, inflammatory cell components in thrombus were investigated. IVC ligation, however, induced the infiltration of F4/80-, CD68-or CD11b-positive macrophages into the thrombus to similar extents in WT and These observations implied that these inflammatory cells would be recruited independently of TNF-Rp55-mediated signals during thrombus formation. We previously identified macrophages as a main source of MMP-2, MMP-9, and PLAU in the thrombus resolution process, 28, 29 and TNF-Rp55 was expressed exclusively on macrophages ( Figure 1D ). Moreover, recombinant TNF-α, anti-TNF-α mAb, or etanercept had few effects on intrathrombotic macrophage accumulation. Thus, we examined the effects of TNF-α on the gene expression of Mmp2, Mmp9, Plau, and Pai1 in peritoneal macrophages derived from WT and Tnfrp55 -/-mice. TNF-α significantly enhanced the gene expression of Mmp2, Mmp9, and Plau but not Pai1 on WT-derived macrophages, whereas it failed to upregulate the gene expression of Mmp2, Mmp9, Plau, and Pai1 in Tnfrp55 -/--derived macrophages ( Figure 5D through 5G). Collectively, these observations implied that the TNF-α-TNF-Rp55 axis could enhance the gene expression of Mmp2, Mmp9, and Plau in macrophages, thereby promoting thrombus resolution.
Effects of TNF-α on NF-κB, ERK, p38 MAPK, and JNK Signaling Pathways
TNF-α significantly enhanced, in macrophages, I-κBα phosphorylation, which represents nuclear localization and activation of NF-κB ( Figure 6A and 6B) . 30 Moreover, TNF-α significantly enhanced the phosphorylation of ERK but not p38 Figure 6A , 6C, and 6D), although it marginally induced JNK phosphorylation ( Figure 6A and 6E) . We further examined the effects of APDC (a NF-κB inhibitor), PD98509 (an ERK inhibitor), and SP600125 (a JNK inhibitor) on TNF-α-mediated increases in Mmp2, Mmp9, and Plau gene expression in macrophages. APDC significantly attenuated TNF-α-induced increase in Mmp2 mRNA expression, whereas PD98509 significantly attenuated TNF-α-induced gene expression of Mmp9 and Plau (Figure 6F through 6H) . In contrast, SP600125 had few effects on TNF-α-induced gene expression of Mmp2, Mmp9, and Plau ( Figure 6F through 6H) . Collectively, TNF-α could induce the expression of Mmp2 through NF-κB activation while it could enhance Mmp9 and Plau gene expression mainly through the ERK pathway.
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Discussion
There remain discrepancies on the roles of TNF-α system in thrombus formation/resolution. [23] [24] [25] TNF-α has in vitro procoagulant roles by inhibiting the synthesis of protein C and stimulating tissue factor in endothelium and monocytes. 31 TNF-α-mediated signaling can initiate the binding of glycoprotein Ib to von Willebrand factor, thereby promoting thrombus formation in a model of photochemical induced arteriolar thrombus. 24 Moreover, TNF-α can favor thrombosis formation by inducing superoxide production, P-selectin, and tissue factor in ferric chloride-induced arteriolar thrombus model. 25 In contrast, TNF-α could decrease platelet activation through rapid NO generation in the vessel wall of the ferric chlorideinduced arteriolar thrombus model. 23 This discrepancy might be attributable to the difference of their experimental models or mouse strain. Moreover, venous thrombi are different from arterial one in terms of the pathological mechanism because of sluggish venous circulation. In the murine venous thrombus model, we demonstrated that TNF-α could have antithrombotic roles in venous thrombosis by enhancing fibrinolysis and collagenolysis. TNF-α-TNF-Rp55 signal pathway is involved in the development of several inflammatory diseases. 17 Indeed, TNF-α played detrimental roles in the development of inflammatory liver disease models. 19, 20 Moreover, we revealed that the deletion of the Tnfrp55 gene accelerated skin wound healing with a concomitant reduction in leukocyte accumulation and collagen deposition. 22 Skin wound healing and thrombus resolution share several pathophysiological features, including initial platelet aggregation, subsequent leukocyte infiltration and collagen deposition, and final neovascularization. TNF-α was mainly expressed in macrophages infiltrating into the thrombus, similarly as observed on those present in skin wound-healing sites. 22 Thus, the TNF-α-TNF-Rp55 axis could have similar roles in thrombus resolution, as in skin wound healing. In contrast to our assumption, Tnfrp55 −/− mice exhibited retarded thrombus resolution as evidenced by larger venous thrombi, compared with WT mice. Moreover, the absence of TNF-Rp55 increased intrathrombotic collagen contents with few effects on macrophage infiltration, compared with WT mice. Thus, the TNF-α-TNF-Rp55 axis had dissimilar effects on thrombus resolution from skin wound healing.
Anti-TNF-α antibody or TNF-α antagonists have been widely used to treat inflammatory conditions including rheumatoid arthritis and inflammatory bowel diseases. There are several case reports that associate the incidence of venous thrombosis with anti-TNF therapy in rheumatoid arthritis 32, 33 and inflammatory bowel disease. 34, 35 A large-scale clinical study, however, negated an increased incidence of venous thrombotic events in rheumatoid arthritis patients treated with anti-TNF therapy. 36 It remains elusive on the effects of anti-TNF therapy on venous thrombotic events in inflammatory bowel disease patients, who are frequently complicated with thromboembolism even without anti-TNF therapy. 37 Our present study suggests that anti-TNF therapy can decrease thrombus resolution but cannot increase the incidence of venous thrombosis, as there was no significant difference in the thrombus size between WT and Tnfrp55 -/-mice until day 5. Neutrophil depletion impaired thrombus resolution while intrathrombus injection of peritoneal macrophages accelerated thrombus resolution. 38, 39 The genetic deletion of CCR2 and that of CXCR2 impaired thrombus resolution with the reduced recruitment of macrophages and neutrophils, respectively. 13, 15 We have also previously revealed the potential contribution of intrathrombotic leukocyte accumulation to thrombus resolution. 40 Accumulating evidence indicates that the TNF-α-TNF-Rp55 axis can regulate leukocyte infiltration through enhancing the expression of adhesion molecules and chemokines. 41 Moreover, the absence of TNF-Rp55 reduced leukocyte recruitment in several disease models. [19] [20] [21] [22] However, in the present model, the genetic deletion of Tnfr55 had few effects on the intrathrombotic number of neutrophils and macrophages, indicating that the TNF-α-TNF-Rp55 axis decelerated thrombus resolution independently of leukocyte infiltration.
The plasmin system plays an important role in clotting, fibrinolysis, inflammatory angiogenesis, and tissue remodeling. 42 Plasmin is produced from plasminogen through the action of the tissue-and urokinase-type plasminogen activator. The balance of plasminogen activators and inhibitors is essential for proteolytic and antiproteolytic activities, and especially, the lack of a major plasminogen activator, PLAU, severely impaired thrombus resolution. 43 TNF-α can regulate gene expression of plasminogen activators and their inhibitor. 44, 45 The gene expression of Plau, but not Pai-1, was attenuated in Tnfrp55 −/− mice and TNF-α augmented Plau mRNA expression by macrophages, a major cell type present in the thrombus. Thus, TNF-α can promote thrombus resolution by enhancing Plau expression.
Venous thrombus is replaced by deposited collagen as time passes, 46 and therefore, thrombus resolution requires collagen degradation. 9 Tnfrp55 -/-mice showed elevated intrathrombotic collagen contents, indicating that the TNF-α-TNF-Rp55 axis was also involved in collagenolysis. Among several enzymes associated with collagenolysis activity, MMP-2 and MMP-9 have important roles in collagen turnover during thrombus resolution. 15, 16 Inflammatory cytokines, such as IL-1 and TNF-α, have been shown to upregulate the gene expression of Mmp2 and Mmp9. 47, 48 The absence of TNF-Rp55 significantly reduced intrathrombotic Mmp2 and Mmp9 mRNA expression and TNF-α enhanced Mmp2 and Mmp9 mRNA expression by macrophages. Thus, the TNF-α-TNF-Rp55 axis promoted thrombus resolution by enhancing Mmp2 and Mmp9 expression with augmented collagenolysis.
Intrathrombotic neovascularization is another essential event for thrombus resolution. Tnfrp55 -/-mice exhibited reduced intrathrombotic neovascularization, compared with WT mice. MMP-2 and MMP-9 can promote neovascularization by mediating basement membrane remodeling of tissue matrix, 49 and the inhibition of MMP-2 or MMP-9 has been shown to impair neovascularization in several conditions such as cardiac ischemia and tumor progression. 50 ,51 PLAU can also induce tumor neovascularization. 52 Thus, the TNF-α-TNF-Rp55 axis could promote intrathrombotic neovascularization by enhancing Plau, Mmp2, and Mmp9 expression.
TNF-α can activate several intracellular signaling pathways, including NF-κB and MAPKs. The TNF-α-TNF-Rp55 interaction activated NF-κB and ERK, but not p38, pathways in macrophages. The activation of NF-κB and ERK is required for the upregulation of Plau in fibroblasts and dental pulp cells. 53, 54 However, the inhibition of ERK pathway, but not NF-κB, reduced TNF-α-mediated Plau expression in macrophages. Li et al 55 demonstrated that IL-17-mediated NF-κB activation enhanced gene expression of Mmp2 and Mmp9 in human hepatocellular carcinoma cell lines. Moreover, ERK activation can lead to enhanced Mmp9 gene expression. 56 In contrast, the inhibition of NF-κB and ERK reduced Mmp2 and Mmp9 expression in macrophages, respectively. The different types of cells used for the experiments may account for the differential responsiveness to the inhibition of each pathway.
Anticoagulant therapy, such as warfarin, is mainly used against deep vein thrombosis to prevent PTE, but it increases the incidence of bleeding complications. Moreover, this therapy cannot induce the resolution of an existing thrombus. Our observations implied that the TNF-α-TNF-Rp55 axis would be a key molecule for thrombus resolution. Moreover, the administration of exogenous TNF-α accelerated thrombus resolution in WT mice after the IVC ligation, but without any effects on coagulation functions. Our previous study demonstrated that immunoneutralization of IFN-γ promoted thrombus resolution through enhancing only MMP-9 expression. 16 In contrast, TNF-α can activate several signal pathways and eventually induce the (gene) expression of Plau, Mmp2, and Mmp9, the enzymes that are essentially involved in collagenolysis and neovascularization. Thus, the TNF-α-TNF-Rp55 axis may be effective to resolute at least venous thrombus.
